Pharmacogenetics: Point-of-care genetic testing - A new frontier explored

Nature Reviews Cardiology

Volumn 9, Issue 6, 2012, Pages 315-316

  Barrett, Paddy M ^a   Topol, Eric J ^a  

^a SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19;

ACUTE CORONARY SYNDROME; ALLELE; CORONARY STENT; GENE SEQUENCE; GENOTYPING TECHNIQUE; HEART INFARCTION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE GENETIC TESTING; POINT OF CARE TESTING; PRIORITY JOURNAL; RISK REDUCTION; SHORT SURVEY; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; ARYL HYDROCARBON HYDROXYLASES; GENETIC TESTING; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE;

EID: 84861479130     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.63     Document Type: Short Survey

References (10)

1. Roberts, J. D. et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet http://dx.doi.org/ 10.1016/S0140-6736(12)60161-5.
2. Mega, J. L. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304, 1821-1830 (2010).
3. Price, M. J. et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J. 29, 992-1000 (2008).
4. Breet, N. J. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303, 754-762 (2010).
5. Bonello, L. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56, 919-933 (2010).
6. Price, M. J. et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124, 1132-1137 (2011).
7. Holmes, M. V., Perel, P., Shah, T., Hingorani, A. D. & Casas, J. P. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306, 2704-2714 (2011).
8. Patay, B. A. & Topol, E. J. The unmet need of education in genomic medicine. Am. J. Med. 125, 5-6 (2012).
9. McCormack, M. et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134-1143 (2011).
10. Chen, P. et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N. Engl. J. Med. 364, 1126-1133 (2011).